A Phase 3 interventional study of Mibavademab in Monogenic Obesity, sponsored by Regeneron Pharmaceuticals. Recruiting at 4 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Obesity, Morbid with a site in Turkey — 8 open to participants now, 8 under way, 1 of them phase 3. Obesity, Morbid · Turkey.
Among the 70 studies in Obesity, Morbid with a site in Turkey, this one is the 37th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 3, and was the 57th registered.
941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.
Browse Obesity, Morbid studies →8 of the 70 studies in Obesity, Morbid with a site in Turkey are open now. Recruiting first, the newest first:
Kocaeli University · Sites in Turkey
Ages 18–80 · Men only
Harran University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 18–65
Gazi University · Sites in Turkey
Ages 18+
Toros University · Sites in Turkey
Ages 19–50
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 110 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 84 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4 is below the median of 62 across 602 interventional studies indexed under Obesity, Morbid.
Median enrollment 66 across the 38 interventional studies, 68 across the 32 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 70 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Morbid with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220772Phase 3Regeneron PharmaceuticalsA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | 2027-06-18 |
| NCT07643376Toros UniversityEvaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management | 2027-01-01 |
| NCT07668765Gazi UniversityGLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | 2027-04 |
| NCT05927519Kocaeli UniversityComparison of Airtraq in Class 2-3 Obese and Nonobese Men During Intubation: a Prospective Randomized Clinical Study | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 70 studies in Obesity, Morbid with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity. Monogenic obesity is caused by a change in the leptin gene that keeps it from working properly. This causes the body to not be able to feel full or control feelings of hunger.
The aim of the study is to see how well mibavademab controls the body weight and how safe it is.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mibavademab
Administered as per the protocol
Also known as: REGN4461
Percent change in Body Mass Index (BMI)
Time frame: Baseline to Week 24
Percent change in BMI
Time frame: Baseline to Week 52
Absolute change in BMI
Time frame: Baseline, Through Week 52
Percent change in body weight
Time frame: Baseline, Through Week 52
Absolute change in body weight
Time frame: Baseline, Through Week 52
Change in waist circumference
Participants aged ≥18 years
Time frame: Baseline, Through Week 52
Change in absolute total fat mass by whole body DXA
Time frame: Baseline, Through Week 52
Change in percent total fat mass by whole body DXA
Time frame: Baseline, Through Week 52
Change in absolute regional fat mass by whole body DXA
Time frame: Baseline, Through Week 52
Change in percent regional fat mass by whole body DXA
Time frame: Baseline, Through Week 52
Change in scores in the symptoms of hyperphagia questionnaire
Symptoms of Hyperphagia - Caregiver Version© is completed by a caregiver. Symptoms of Hyperphagia - Patient Version© is completed by the participants who are aged \<12 years or for participants who are unable to self-complete. The questionnaires both assesses the frequency of hunger symptoms on a categorical scale (Never, 1 or 2 times, 3 or more times) over the past 24 hours and are scored combining the total scores across the items. Higher scores indicate greater severity.
Time frame: Baseline, Through Week 52
Change in scores in the impacts of hyperphagia questionnaire
For participants who are aged \<12 years or for participants who are unable to self-complete, the Impacts of Hyperphagia - Caregiver Version© is completed by a caregiver. For participants aged ≥12 years who are able to self-report, the Impacts of Hyperphagia - Patient Version© is completed by the participant. Both questionnaires assess the impact of hyperphagia on a categorical scale (range: not at all, a little, moderately, a great deal). The participant version is scored using a total score across the 5 items. The caregiver version is scored separately for each section. Higher scores indicate a greater impact of hyperphagia.
Time frame: Baseline, Through Week 52
Change in scores in the hunger questionnaire
The Daily Hunger Assessment is a daily, single item measuring hunger for participants aged ≥12 years who are able to self-complete, participants are asked to rate their highest level of hunger over for the day, where "0" is "not hungry at all" to "10" the hungriest possible."
Time frame: Baseline, Through Week 52
Number of treatment-emergent adverse events (TEAEs)
Time frame: Through Week 65
Severity of TEAEs
Time frame: Through Week 65
Concentrations of total mibavademab in serum
Time frame: Through Week 65
Incidence of anti-drug antibody (ADA) to mibavademab
Time frame: Through Week 65
Titer of ADA to mibavademab
Time frame: Through Week 65
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mibavademab